Amyotrophic lateral sclerosis: a double-blind crossover trial of thyrotropin-releasing hormone.

AUTOR(ES)

Imoto, K

RESUMO

A double-blind crossover trial was conducted of thyrotropin releasing hormone treatment in six patients with amyotrophic lateral sclerosis. Patients received 4 mg of thyrotropin releasing hormone intramuscularly daily during the two-week treatment period. Although three patients reported subjective improvement, objective evaluation failed to demonstrate therapeutic effectiveness of thyrotropin releasing hormone in this dosage.

Documentos Relacionados

• Naproxen in osteoarthrosis. Double-blind crossover trial.
• Cloning of a cDNA encoding an ectoenzyme that degrades thyrotropin-releasing hormone.
• Hyperbaric oxygen and multiple sclerosis: final results of a placebo-controlled, double-blind trial.
• The Ups and Downs of Thyrotropin-Releasing Hormone
• Assessment of Thyrotropin-Releasing Hormone and Thyrotropin Reserve in Man